Long-term raloxifene for postmenopausal osteoporosis

Posted by: admin on: March 7, 2012

With increase in life expectancy post menopausal osteoporosis needs to be attended to with life long maintenance drug to increase one’s BMD. In this article Raloxifene’s long term efficiency has been proved.


Due to the chronic nature of osteoporosis and the risk of invasive breast cancer, raloxifene 60 mg/day (raloxifene) is intended to be used for long-term treatment (treatment>3 years).

We review available information concerning long-term use of raloxifene, present several new analyses, and report new data from patients who underwent iliac crest bone biopsies after 8 years of raloxifene therapy. The most important studies were the Multiple Outcomes of Raloxifene Evaluation (MORE) followed by the Continued Outcomes of Raloxifene Evaluation (CORE).

The primary endpoint in MORE was incidence of vertebral fracture, and the difference between the raloxifene and placebo groups for this endpoint widened during 4 years of therapy, with the relative risk reduction during the fourth year of the study being similar to the relative risk reduction during years 0 to 3 of the study. Continued raloxifene treatment is necessary to preserve bone mineral density (BMD). In MORE, raloxifene lowered markers of bone turnover to a premenopausal reference interval. Biopsies from three patients treated with raloxifene for 8 years showed normal bone and bone cells and double label in all specimens. Invasive breast cancer risk is a clinical consideration in postmenopausal women with osteoporosis, and invasive breast cancer risk reduction was the primary endpoint in CORE.

In MORE and CORE, the benefit of raloxifene versus placebo in incidence of invasive breast cancer increased with greater duration of therapy up to 8 years.
Conclusions: The long-term use of raloxifene has been evaluated through changes in fracture risk reduction, BMD, markers of bone turnover, iliac crest bone biopsies, and invasive breast cancer risk reduction.

Ref: http://www.docguide.com/long-term-raloxifene-postmenopausal-osteoporosis?hash=80445d1a&eid=21468&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2

Leave a Reply

Your email address will not be published. Required fields are marked *


CMHF Accredited by Maharashtra Medical Council

Subscribe to our Posts

Enter your email address:

  • drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
  • rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
  • nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards

Calculate Your Body Mass Index

Check your Body Mass Index »

    Peach - 60 kcal in 100g
    Peach - 60 kcal in 100g
    by Noni